Obermatt

Harmony Biosciences Holdings

NMQ:HRMY · US4131971040
PharmaceuticalsMedium

360

94
EV / EBIT100
Price / Owner Earnings45
Owner Earnings Yield92
Dividend Yield1
Price/Sales84
EV / Gross Profit95
Price/Book65
Return on Capital95
Cash Return on Capital90
Return on Equity86
EBIT Margin75
Gross Profitability91
Cash Conversion83
Accruals37
Owner Earnings Margin79
Sales growth60
Profit Growth91
Long-Term EPS Growth71
Owner Earnings Growth38
Reinvestment34
Price momentum37
Debt load48
Refinancing26
Debt Payback100
Liquidity83
Analyst ratings14
Opinion Changes50
Price Target Upside20
Market mood83
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Harmony Biosciences Holdings generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeNASDAQGM
Founded2017
Employees292
ISINUS4131971040
Last UpdateApr 2, 2026
Themes
NeurologyCannabisSleep TechnologyPsychiatryCentral Nervous SystemGenetic Disorder

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing innovative therapies for patients living with rare neurological disorders as well as patients living with other neurological dise…

Analysis

Hidden champion

Harmony Biosciences Holdings, Inc. is what we call a hidden champion: a strong business that the market is not pricing as one.

The price is attractive. You pay 11.9× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -1% yearly growth; analysts expect 21%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is sturdy. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
88
2023202420252026

All-time high

98

Jan 2025

All-time low

34

Jan 2024

Average rank

74

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
41
31
28
Price/Earnings
36
67
85
64
Price/Book
65
31
18
4
Dividend Yield
1
1
1
1
Value (overall)
72
32
34
17

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Harmony Biosciences Holdings with its peers
Omeros
NMQ:OMER
29
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Adicet Bio
NAQ:ACET
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
EyePoint
NMQ:EYPT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Abeona Therapeutics
NAQ:ABEO
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
LB Pharmaceuticals
NMQ:LBRX
79
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →